Caring Brands, Inc. (NASDAQ:CABR) Short Interest Update

Caring Brands, Inc. (NASDAQ:CABR) saw a significant increase in short interest in June. As of June 15th, there was short interest totaling 63,992 shares, an increase of 207.7% from the May 31st total of 20,796 shares. Based on an average daily trading volume, of 85,538 shares, the days-to-cover ratio is presently 0.7 days. Approximately 0.8% of the shares of the stock are short sold.

Caring Brands Trading Down 2.1%

Shares of CABR traded down $0.03 during trading hours on Monday, hitting $1.19. 12,044 shares of the stock traded hands, compared to its average volume of 114,371. The firm has a fifty day simple moving average of $1.12. The stock has a market capitalization of $10.77 million and a price-to-earnings ratio of -1.85. Caring Brands has a 1-year low of $0.71 and a 1-year high of $5.35. The company has a quick ratio of 5.62, a current ratio of 5.66 and a debt-to-equity ratio of 0.03.

Caring Brands (NASDAQ:CABR) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.27) earnings per share for the quarter.

Institutional Trading of Caring Brands

A hedge fund recently bought a new stake in Caring Brands stock. Jane Street Group LLC bought a new position in shares of Caring Brands, Inc. (NASDAQ:CABR) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned 0.25% of Caring Brands at the end of the most recent quarter.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 11th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Caring Brands

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.